Germany’s Merck KGaA MKGAF will invest €25 million in its Molsheim, France facility to make disposable materials for bioreactors, an essential material required for COVID-19 vaccine manufacturing.
- The new site will see the creation of 350 jobs, along with 1,700 square meters of cleanrooms.
- The new unit will produce Mobius single-use assemblies. It is planned to be operational by the end of this year.
- Molsheim will be the first site in Europe where the Life Science business sector manufactures the product. Further production sites are located in Danvers, Massachusetts, and Wuxi, China.
- Price Action: MKAGF shares are trading 1% lower at $162.32 in market trading hours on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.